Bortezomib-based induction treatment prior to autologous stem cell transplantation (ASCT): results of randomized studies.
| Author . | Harousseau20 . | Cavo31 . |
|---|---|---|
| Abbreviations: VD, vincristine, dexamethasone; VAD, vincristine, doxorubicin, dexamethasone; VTD, thalidomide, dexamethasone, bortezomid; TD, thalidomide, dexamethasone; CR, complete response; n-CR, near CR; VGPR, very good partial response; PR, partial response | ||
| Treatment | VD vs VAD (4 cycles) | VTD vs TD (3 cycles) |
| Number of patients | 482 | 256 |
| Results prior to ASCT, % | ||
| CR + n-CR | 21 vs 8 | 36 vs 9 |
| > VGPR | 47 vs 19 | 60 vs 27 |
| > PR | 80 vs 63 | 93 vs 80 |
| CR + n-CR in patients with del(13) | 26 vs 9 | 43 vs 4 |
| Results after ASCT, % | ||
| CR + n-CR | 35 vs 24 | 57 vs 28 |
| > VGPR | 62 vs 42 | 77 vs 54 |
| Peripheral neuropathy grade 3, % | 6 | 7 |
| Author . | Harousseau20 . | Cavo31 . |
|---|---|---|
| Abbreviations: VD, vincristine, dexamethasone; VAD, vincristine, doxorubicin, dexamethasone; VTD, thalidomide, dexamethasone, bortezomid; TD, thalidomide, dexamethasone; CR, complete response; n-CR, near CR; VGPR, very good partial response; PR, partial response | ||
| Treatment | VD vs VAD (4 cycles) | VTD vs TD (3 cycles) |
| Number of patients | 482 | 256 |
| Results prior to ASCT, % | ||
| CR + n-CR | 21 vs 8 | 36 vs 9 |
| > VGPR | 47 vs 19 | 60 vs 27 |
| > PR | 80 vs 63 | 93 vs 80 |
| CR + n-CR in patients with del(13) | 26 vs 9 | 43 vs 4 |
| Results after ASCT, % | ||
| CR + n-CR | 35 vs 24 | 57 vs 28 |
| > VGPR | 62 vs 42 | 77 vs 54 |
| Peripheral neuropathy grade 3, % | 6 | 7 |